SABCS 2014: ER Positive Breast Cancer Treatments
As the 37th annual San Antonio Breast Cancer Symposium (SABCS) drew to a close, a range of intriguing clinical observations and long-awaited trial updates had made the event a valuable experience for investigators and attendees alike. Among some of the most interesting updates, in my opinion, were advancements in treatments for estrogen receptor-positive (ER-positive) breast cancer, premenopausal breast cancers and advanced breast cancers.
ER Positive Breast Cancers
Results from the FERGI trial were presented at this year’s meeting. This trial is investigating the new agent pictilisib, which belong to a new class of drugs called PI3K inhibitors that […]
Kadcyla, approved by the U.S. Food and Drug Administration (FDA) in February 2013, is one of the latest advancements to improve our ability to treat breast cancer. Although Kadcyla was only approved for a specific population of breast cancer patients (HER2 positive breast cancer that has spread to other parts of the body (metastatic breast cancer)), it fits into a larger story that is fundamentally changing how we treat many types of breast cancer.
Pertuzumab (Perjeta) became the first drug to ever be approved by the FDA for use prior to surgery for non-metastatic breast cancer on September 30, 2013. This development further signals a paradigm shift away from chemotherapy and towards targeted therapy – specifically in the now increasingly target-rich environment of HER2-positive breast cancer.
[…]
